International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) Meeting Abstract
| Authors: | Kaufmann, P.; Cortes, J.; Martin, M.; Mayer, I.; Vahdat, L.; Pernas, S.; Schmid, P.; McArthur, H.; Dent, R.; Rugo, H.; Barrios, C.; Barker, D.; Romagnoli, B.; Bobirca, A. |
| Abstract Title: | International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500101 |
| DOI: | 10.1158/1538-7445.Sabcs19-ot1-08-06 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-08-06 -- Title is mistakenly duplicated in the publisher's record and SABCS website -- Source: Wos |
